Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

MLA

Levy, Moshe Yair, et al. “Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML).” Blood, vol. 126, no. 23, Dec. 2015, p. 1588. EBSCOhost, https://doi.org/10.1182/blood.V126.23.1588.1588.

APA

Levy, M. Y., McGarry, L. J., Lustgarten, S., Yang, M., & Haluska, F. G. (2015). Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML). Blood, 126(23), 1588. https://doi.org/10.1182/blood.V126.23.1588.1588

Chicago

Levy, Moshe Yair, Lisa J. McGarry, Stephanie Lustgarten, Mo Yang, and Frank G. Haluska. 2015. “Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML).” Blood 126 (23): 1588. doi:10.1182/blood.V126.23.1588.1588.